Your session is about to expire
← Back to Search
Belantamab Mafodotin for Multiple Myeloma
Study Summary
This trial is testing a new cancer drug, given with standard treatment, to see if it is safe and works better than the standard treatment alone.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have active hepatitis B or I agree to preventive treatment if I have been exposed.I do not have an infection that needs antibiotics.I do not have an active kidney condition that could affect my safety in the trial, except for proteinuria due to MM.I do not have any current bleeding from my internal organs or mucous membranes.I do not have any serious eye surface (corneal) diseases.I am approved to receive a specific chemotherapy dose.I started treatment for my multiple myeloma less than a year ago.I have no other cancers, or any I do have are stable and won't affect this trial.I do not have an active HIV infection or my HIV is well-controlled with treatment.I have not had any major surgery in the last 4 weeks.I do not have amyloidosis or POEMS syndrome.I haven't had monoclonal antibody treatment in the last 28 days.I do not have active hepatitis C.I've had up to 2 initial treatments for my condition without worsening.My liver is stable without severe problems like ascites or cirrhosis.I haven't taken any experimental drugs or standard myeloma treatments in the last 14 days or five half-lives, whichever is shorter.I do not have any heart-related health risks.I can take care of myself and am up and about more than half of my waking hours.My organs and bone marrow are working well.You should not have had a bad reaction to belantamab mafodotin or similar drugs in the past.I am eligible for lenalidomide treatment after my stem cell transplant.My cancer has partially responded to treatment, but is not completely gone after 4 treatment cycles.
- Group 1: Belantamab mafodotin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current allotment for participants in this experiment?
"Affirmative. The clinicaltrials.gov website indicates that this study, first published on May 25th 2021, is actively searching for 47 people to participate in the trial at 1 location. It was last updated on June 13th 2022."
What other experiments have been conducted to assess the efficacy of Belantamab mafodotin?
"At present, 33 clinical trials are examining the efficacy of Belantamab mafodotin. 4 of these studies have ascended to Phase 3 and over 875 sites around the world are administering this potential treatment. Specifically, many locations in Poitiers cedex, Baden-Wuerttemberg are conducting research on Belantamab mafodotin."
Are there any available slots for participants in this clinical experiment?
"Yes, per the details on clinicaltrials.gov, this research is actively seeking participants. The study was first posted May 25th 2021 and most recently updated June 13th 2022. It is currently looking for 47 volunteers at a single location."
Is this research pioneering in nature?
"Karyopharm Therapeutics Inc., initiated the first Belantamab mafodotin trial back in 2015, with 518 participants. Subsequently this drug earned its Phase 1 & 2 certification and is now being investigated across 221 cities of 34 different countries; there are currently 33 active clinical studies for Belantamab mafodotin."
What conditions is Belantamab mafodotin utilized to address?
"Belantamab mafodotin is typically prescribed to induce immunomodulation. It can also be used in multiple myeloma patients who have experienced relapse or refractoriness after a proteasome inhibitor and/or anti-CD38 monoclonal antibody treatment."
To what extent can Belantamab mafodotin cause harm to individuals?
"The safety assessment of belantamab mafodotin was determined to be a 2, since there is some clinical data confirming its safety but none for efficacy."
Share this study with friends
Copy Link
Messenger